Datapoint: FDA Postpones Review for Lilly’s Alzheimer’s Drug

The FDA will take longer than expected to make a decision on Eli Lilly & Co.’s donanemab. The Alzheimer’s drug was originally slated for an approval decision as early as this week. According to NBC News, the FDA informed Lilly that it wants more data on the drug’s safety and effectiveness. If approved, the drug would compete with Eisai Co., Ltd. and Biogen Inc.’s Leqembi (Iecanemab-irmb). The controversial therapy holds covered or better status for just 36% of all insured lives.

SOURCE: MMIT Analytics, as of 3/18/24

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 22

Datapoint: Georgia Medicaid Work Program Sees Slow Start

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 18

Datapoint: Arcutis Scores New Indication for Zoryve

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
July 17

Datapoint: Blue Shield of California Adds New Weight Loss, Diabetes Programs to Digital Health Platform

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today